Raul Mena

1.8k total citations
18 papers, 418 citations indexed

About

Raul Mena is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Raul Mena has authored 18 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 5 papers in Genetics. Recurrent topics in Raul Mena's work include Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Bone health and treatments (3 papers). Raul Mena is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Bone health and treatments (3 papers). Raul Mena collaborates with scholars based in United States, United Kingdom and Hungary. Raul Mena's co-authors include R. Lambert-Falls, Adam Brufsky, Nigel Bundred, Peyman Hadji, Lixian Jin, Solveig G. Ericson, Carlos Argüello, Robert E. Coleman, Juan B. Kourí and J.A. Caminero Luna and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Raul Mena

18 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raul Mena United States 9 252 107 84 71 68 18 418
M. Collette France 11 398 1.6× 251 2.3× 97 1.2× 121 1.7× 37 0.5× 15 644
Luqiang Wang United States 12 222 0.9× 148 1.4× 45 0.5× 37 0.5× 34 0.5× 26 508
Kazuya Takemura Japan 10 212 0.8× 69 0.6× 27 0.3× 47 0.7× 17 0.3× 28 431
Zahida Saad Canada 8 220 0.9× 194 1.8× 31 0.4× 121 1.7× 22 0.3× 11 456
Elizabeth C. O’Quinn United States 9 95 0.4× 218 2.0× 38 0.5× 89 1.3× 60 0.9× 14 478
Brittany Campbell United States 6 145 0.6× 103 1.0× 15 0.2× 73 1.0× 20 0.3× 11 300
M. Walraven Netherlands 10 87 0.3× 176 1.6× 30 0.4× 48 0.7× 27 0.4× 11 563
S G Senaratne United Kingdom 6 596 2.4× 193 1.8× 285 3.4× 86 1.2× 103 1.5× 7 694
P. Hirnle Germany 11 250 1.0× 91 0.9× 108 1.3× 63 0.9× 25 0.4× 31 454

Countries citing papers authored by Raul Mena

Since Specialization
Citations

This map shows the geographic impact of Raul Mena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raul Mena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raul Mena more than expected).

Fields of papers citing papers by Raul Mena

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raul Mena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raul Mena. The network helps show where Raul Mena may publish in the future.

Co-authorship network of co-authors of Raul Mena

This figure shows the co-authorship network connecting the top 25 collaborators of Raul Mena. A scholar is included among the top collaborators of Raul Mena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raul Mena. Raul Mena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Fowler, Nathan, Loretta J. Nastoupil, Sven de Vos, et al.. (2020). The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma. British Journal of Haematology. 189(4). 650–660. 20 indexed citations
2.
Picozzi, Vincent J., Joseph W. Leach, John E. Seng, et al.. (2017). Initial gemcitabine/nab-paclitaxel (GA) followed by sequential (S) mFOLFIRINOX or alternating (A) mFOLFIRI in metastatic pancreatic cancer (mPC): The SEENA-1 study.. Journal of Clinical Oncology. 35(4_suppl). 359–359. 5 indexed citations
3.
4.
5.
Fowler, Nathan, Loretta J. Nastoupil, Sven de Vos, et al.. (2016). Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. Blood. 128(22). 1804–1804. 6 indexed citations
6.
Fowler, Nathan, Loretta J. Nastoupil, Sven de Vos, et al.. (2015). Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. Blood. 126(23). 470–470. 23 indexed citations
7.
Saltzman, Marc, Alberto Bessudo, Roger M. Lyons, et al.. (2015). Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis. Blood. 126(23). 4074–4074. 1 indexed citations
8.
Ramanathan, Ramesh K., Peter P. Lee, John E. Seng, et al.. (2014). Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology. 32(3_suppl). 224–224. 6 indexed citations
9.
Sinicropi, Dominick, Kunbin Qu, François Collin, et al.. (2012). Whole Transcriptome RNA-Seq Analysis of Breast Cancer Recurrence Risk Using Formalin-Fixed Paraffin-Embedded Tumor Tissue. PLoS ONE. 7(7). e40092–e40092. 59 indexed citations
10.
11.
Yao, James C., A.B. Benson, Anne Thomas, et al.. (2008). A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology. 63(2). 363–370. 50 indexed citations
12.
Brufsky, Adam, Nigel Bundred, Robert E. Coleman, et al.. (2008). Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. The Oncologist. 13(5). 503–514. 134 indexed citations
13.
14.
Garrison, L., J Cassidy, MN Saleh, et al.. (2007). Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer. Journal of Clinical Oncology. 25(18_suppl). 4074–4074. 14 indexed citations
15.
16.
McCloskey, Susan A., Leslie E. Botnick, Christopher M. Rose, et al.. (2006). Long-term Outcomes after Breast Conservation Therapy for Early Stage Breast Cancer in a Community Setting. The Breast Journal. 12(2). 138–144. 7 indexed citations
17.
18.
Kourí, Juan B., Carlos Argüello, J.A. Caminero Luna, & Raul Mena. (1998). Use of microscopical techniques in the study of human chondrocytes from osteoarthritic cartilage: An overview. Microscopy Research and Technique. 40(1). 22–36. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Collette Breakdown of academic impact, for papers by Luqiang Wang Breakdown of academic impact, for papers by Kazuya Takemura Breakdown of academic impact, for papers by Zahida Saad Breakdown of academic impact, for papers by Elizabeth C. O’Quinn Breakdown of academic impact, for papers by Brittany Campbell Breakdown of academic impact, for papers by M. Walraven Breakdown of academic impact, for papers by S G Senaratne Breakdown of academic impact, for papers by P. Hirnle
Rankless by CCL
2026